首页> 外文期刊>Cardiovascular therapeutics >Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE?/? mice
【24h】

Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE?/? mice

机译:Warfarin,但不是Rivaroxaban,促进了Apoe中主动脉瓣的钙化?/? 老鼠

获取原文
获取原文并翻译 | 示例
           

摘要

Summary Introduction Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma‐carboxylation of Matrix‐Gla‐Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification. Aims To compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice. Results 42 ApoE?/? mice fed with Western‐type Diet ( WTD ) were randomized to treatment with warfarin (n?=?14), rivaroxaban (n?=?14) or control (n?=?14) for 8?weeks. Histological analyses were performed to quantify the calcification of aortic valve leaflets and the development of atherosclerosis. The analyses showed a significant increase in valve calcification in mice treated with warfarin as compared to WTD alone ( P ?=?.025) or rivaroxaban ( P ?=?.005), whereas no significant differences were found between rivaroxaban and WTD ( P ?=?.35). Quantification of atherosclerosis and intimal calcification was performed on the innominate artery of the mice and no differences were found between the 3 treatments as far as atherogenesis and calcium deposition is concerned. In vitro experiments performed using bovine interstitial valve cells ( VIC ) showed that treatment with rivaroxaban did not prevent the osteogenic conversion of the cells but reduce the over‐expression of COX ‐2 induced by inflammatory mediators. Conclusion We showed that warfarin, but not rivaroxaban, could induce calcific valve degeneration in a mouse model of atherosclerosis. Both the treatments did not significantly affect the progression of atherosclerosis. Overall, these data suggest a safer profile of rivaroxaban on the risk of cardiovascular disease progression.
机译:发明内容揭示了维生素K拮抗剂,如华法林,通过阻断基质-Gla蛋白的γ-羧化促进动脉钙化。目前未知是否是因子Xa的诸如直接抑制剂的其他口腔抗凝血剂可以对主动脉瓣钙化的进展具有保护作用。旨在比较华法林和蓖麻毒素对动脉粥样硬化小鼠主动脉瓣钙化进展的比较。结果42 Apoe?/?用西方饮食(WTD)喂养的小鼠随机用华法林(n?=Δ14),rivaroxaban(n?=Δ14)或控制(n?= 34),8?周。进行组织学分析以量化主动脉瓣叶的钙化和动脉粥样硬化的发展。与单独的WTD相比,通过WTD(p?= 025)或raivaroxaban(p?=α.005)与WTD处理的小鼠中瓣膜钙化的显着增加(p?= 005),而Rivaroxaban和WTD之间没有显着差异(P ?=?35)。对小鼠的无名动脉进行动脉粥样硬化和内膜钙化的定量,并且在3个处理中没有发现静脉发生和钙沉积没有差异。使用牛间质瓣膜细胞(VIC)进行的体外实验表明,用rivaroxaban治疗没有防止细胞的成骨转化,但减少炎症介质诱导的COX -2的过表达。结论我们表明,华法林,但不是罗昔扎班,可以在动脉粥样硬化的小鼠模型中诱导钙化瓣膜变性。两种治疗都没有显着影响动脉粥样硬化的进展。总的来说,这些数据表明Rivaroxaban对心血管疾病进展风险更安全的轮廓。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号